Table 3.
Count of NEISS-CADES Cases and Projected National Estimates of US Emergency Department Visits Stratified by Fluoroquinolone and Hypersensitivity Reaction Severity Category, 2004–2010
| All Reaction Severity Categories | Mild Reactions | Moderate to Severec Reactions | ||||
|---|---|---|---|---|---|---|
| Fluoroquinolone | Number of NEISS-CADES Cases | Estimated Number of ED Visits (95% CI) | Number of NEISS-CADES Cases | Estimated Number of ED Visits (95% CI) | Number of NEISS-CADES Cases | Estimated Number of ED Visits (95% CI) |
| Ciprofloxacin | 469 | 32,269 (25,271–39,265) | 321 | 22,523 (16,906–28,138) | 148 | 9,746 (7,247–12,244) |
| Levofloxacin | 505 | 35,947 (27,617–44,276) | 311 | 22,028 (16,499–27,556) | 194 | 13,918 (10,164–17,672) |
| Moxifloxacin | 448 | 34,469 (24,148–44,789) | 265 | 20,104 (12,966–27,212) | 183 | 14,365 (9,781–18,948) |
| All Analyzablea Fluoroquinolones | 1422 | 102,684 (81,026–124,342) | 897 | 64,655 (50,819–78,490) | 525 | 38,029 (28,539–47,518) |
| All Fluoroquinolonesb | 1440 | 104,338 (82,047–126,628) | 910 | 65,901 (51,750–80,051) | 530 | 38,437 (28,680–48,194) |
Source data: NEISS-CADES database 2004–2010 Extracted November 9, 2012
a
Includes cases attributed to ciprofloxacin, levofloxacin and moxifloxacin only.
b
Includes cases attributed to ciprofloxacin, levofloxacin, moxifloxacin, gemifloxacin and ofloxacin. There were no cases of norfloxacin attributed hypersensitivity in the NEISS-CADES system.
c
Moderate to severe reactions are pooled cases of moderate and severe reactions from the NEISS-CADES system.